CV1-Fc

CV1-Fc is a high-affinity recombinant fusion protein designed to block the CD47-SIRPα "don't eat me" signaling pathway. It consists of the CV1 variant of the Signal Regulatory Protein alpha (SIRPα) D1 domain, which was computationally engineered to bind CD47 with approximately 50,000-fold higher affinity than the wild-type protein, fused to an immunoglobulin Fc region. By binding to CD47 on tumor cells, CV1-Fc prevents its interaction with SIRPα on macrophages, thereby relieving the inhibition of phagocytosis and promoting the clearance of cancer cells. CV1-Fc is frequently utilized in preclinical research as a potent CD47 antagonist and has been explored as a secreted payload in adoptive T-cell therapies (such as TCR-T cells) to localize CD47 blockade and enhance the innate immune response within the tumor microenvironment.

Other names

high-affinity SIRPα decoy-FcSIRPα(CV1)-Fc